GeneCure has developed a patented gene transfer technology (SimVec™) based on a primate lentivirus, the simian immunodeficiency virus (SIV). This novel gene transfer technology has the ability to efficiently and stably deliver genes into primary human cells without causing harm to humans. The SimVec™ gene transfer technology can be used for countless gene transfer applications including but not limited to the production or transgenic animals, stem cell manipulation, vaccine development, and gene discovery. SimVec™ will be marketed as a basic research tool. In addition, GeneCure will license this technology to other organizations developing gene-based therapeutics for human diseases.
